What is the value of screening for prostate cancer in the US?
- 1 November 2005
- journal article
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 2 (11) , 536-537
- https://doi.org/10.1038/ncponc0348
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Radical Prostatectomy versus Watchful Waiting in Early Prostate CancerNew England Journal of Medicine, 2005
- 20-Year Outcomes Following Conservative Management of Clinically Localized Prostate CancerJAMA, 2005
- THE PROSTATE SPECIFIC ANTIGEN ERA IN THE UNITED STATES IS OVER FOR PROSTATE CANCER: WHAT HAPPENED IN THE LAST 20 YEARS?Journal of Urology, 2004
- Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical ProstatectomyNew England Journal of Medicine, 2004
- Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per MilliliterNew England Journal of Medicine, 2004
- Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate CancerJNCI Journal of the National Cancer Institute, 2003
- Variation of Serum Prostate-Specific Antigen LevelsJAMA, 2003
- Prostate Specific Antigen Based Biennial Screening is Sufficient to Detect Almost All Prostate Cancers While Still CurableJournal of Urology, 2003
- Gleason Score 2–4 Adenocarcinoma of the Prostate on Needle BiopsyThe American Journal of Surgical Pathology, 2000
- Advances in Diagnostic Imaging and Overestimations of Disease Prevalence and the Benefits of TherapyNew England Journal of Medicine, 1993